STAT+: In Duchenne muscular dystrophy, a promising therapy is available to a fortunate few
Exon-skipping drugs present a critical test for the FDA’s goal of encouraging treatments for rare disease.
We haven't written up this one. STAT News has the full story — the link below goes straight to it.